--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-26-253709" form_type: "8-K" ticker: "CUE" cik: "0001645460" company_name: "Cue Biopharma, Inc." filed_at: "2026-06-02T20:45:51+00:00" generated_at: "2026-06-02T20:47:30.253845+00:00" event_type: "leadership" sentiment: "neutral" materiality_score: 0.6 calibrated_materiality_score: 0.6 confidence: "high" source: SEC EDGAR --- # Cue Biopharma appoints new directors, chief legal officer, and accounting officer; board size reduced ## Summary - Resignations of directors Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen effective May 29, 2026. - Sumita Ray appointed Chief Legal & Compliance Officer and Corporate Secretary on June 1, 2026. - Michael Meluzio appointed VP, Principal Accounting Officer on June 1, 2026. - Daniel Camardo and Viola Meehan appointed as directors on May 30, 2026; board reduced from seven to five. ## SEC filing metadata - accession: 0001193125-26-253709 - form_type: 8-K - ticker: CUE - cik: 0001645460 - company_name: Cue Biopharma, Inc. - filed_at: 2026-06-02T20:45:51+00:00 - event_type: leadership - sentiment: neutral - materiality_score: 0.6 - calibrated_materiality_score: 0.6 - confidence: high - sec_items: 5.02, 8.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/d139032d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-26-253709 - JSON: https://secwatch.observer/filing/0001193125-26-253709.json - Plain text: https://secwatch.observer/filing/0001193125-26-253709.txt ## Source-grounded claims - claim_id: 0315e9ae30 claim: Patrick Verheyen departed as member of the Board of Directors at Cue Biopharma, Inc.. evidence_excerpt: On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately. evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm - claim_id: 2ca23b462b claim: Peter Kiener departed as member of the Board of Directors at Cue Biopharma, Inc.. evidence_excerpt: On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately. evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm - claim_id: 2e4f2ed2c4 claim: Daniel Camardo was appointed as director at Cue Biopharma, Inc.. evidence_excerpt: On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified. evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm - claim_id: 573c096941 claim: Viola Meehan was appointed as director at Cue Biopharma, Inc.. evidence_excerpt: On May 30, 2026, the Board appointed each of Daniel Camardo and Viola Meehan as directors of the Company, to hold office for a one-year term and until his or her resignation or removal or his or her successors are duly elected and qualified. evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm - claim_id: 7d66bf3983 claim: Michael Meluzio was appointed as Vice President, Principal Accounting Officer at Cue Biopharma, Inc.. evidence_excerpt: On June 1, 2026, the Board appointed Michael Meluzio as the Company’s Vice President, Principal Accounting Officer, to serve as the Company’s principal accounting officer, effective June 1, 2026. evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm - claim_id: ab86580cc7 claim: Sumita Ray was appointed as Chief Legal & Compliance Officer and Corporate Secretary at Cue Biopharma, Inc.. evidence_excerpt: On June 1, 2026, the Board appointed Sumita Ray, JD, as the Company’s Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026. evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm - claim_id: b26c64a588 claim: Colin Sandercock changed role as Senior Vice President, Intellectual Property at Cue Biopharma, Inc.. evidence_excerpt: Mr. Sandercock will continue to serve as the Company’s Senior Vice President, Intellectual Property. evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm - claim_id: d9e64a264b claim: Jill Broadfoot departed as member of the Board of Directors at Cue Biopharma, Inc.. evidence_excerpt: On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately. evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm - claim_id: f71a876bae claim: Frank Morich departed as member of the Board of Directors at Cue Biopharma, Inc.. evidence_excerpt: On May 29, 2026, Cue Biopharma, Inc. (the “Company”) and each of Jill Broadfoot, Peter Kiener, Frank Morich and Patrick Verheyen mutually agreed that Messrs. Kiener, Morich and Verheyen and Ms. Broadfoot would resign as members of the Board of Directors of the Company (the “Board”) and as members of the committees of the Board on which they serve, effective immediately. evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.